Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

Rhea-AI Summary

Acadia Pharmaceuticals will report its fourth quarter and full year 2021 financial results on February 28, 2022, after U.S. market close. A conference call to discuss these results is scheduled for 4:30 p.m. Eastern Time on the same day. Participants can access the call via phone or through a live webcast on Acadia's website, where the session will be archived until March 28, 2022. The company has a strong focus on neuroscience and has developed treatments for Parkinson’s disease psychosis and is working on therapies for dementia-related psychosis and schizophrenia.

Positive

• Acadia's drug for hallucinations and delusions in Parkinson’s disease has been commercialized.
• The company is advancing its pipeline for treating dementia-related psychosis and schizophrenia.

Negative

• No specific financial data or revenue guidance was provided, leaving uncertainty for investors.

Company to host conference call and webcast on Monday, February 28, 2022, at 4:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2021 financial results on Monday, February 28, 2022, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 28, 2022, at 4:30 p.m. Eastern Time to discuss financial results and operations.

The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-4067 for international callers (reference passcode 6887457). A telephone replay of the conference call may be accessed through March 14, 2022 by dialing 855-859-2056 for callers in the United States or Canada and 404-537-3406 for international callers (reference passcode 6887457). The conference call also will be webcast live on Acadia’s website, www.acadia-pharm.com under the investors section and will be archived there until March 28, 2022.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on treating psychosis in patients with dementia, the negative symptoms of schizophrenia and Rett syndrome. Our early-stage development efforts are focused on novel approaches to pain management, cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn and Twitter.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements regarding the timing of future events. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization. For a discussion of these and other factors, please refer to Acadia’s annual report on Form 10-K for the year ended December 31, 2020 as well as Acadia’s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Acadia undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220214005131/en/

Media Contact:

Acadia Pharmaceuticals Inc.

Deb Kazenelson

(818) 395-3043

media@acadia-pharm.com

Investor Contact:

Acadia Pharmaceuticals Inc.

Mark Johnson, CFA

(858) 261-2771

ir@acadia-pharm.com

 

Source: Acadia Pharmaceuticals Inc.

FAQ

When will Acadia Pharmaceuticals report financial results?

Acadia Pharmaceuticals will report its financial results for the fourth quarter and full year 2021 on February 28, 2022.

What time is the Acadia Pharmaceuticals conference call?

The conference call will take place on February 28, 2022, at 4:30 p.m. Eastern Time.

How can I access the conference call for Acadia Pharmaceuticals?

You can access the conference call by dialing 855-638-4820 for U.S. participants or 443-877-4067 for international callers.

What is Acadia Pharmaceuticals focused on in its drug development?

Acadia Pharmaceuticals is focused on advancing treatments for psychosis in dementia, negative symptoms of schizophrenia, and pain management in CNS disorders.